Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Johnson and Johnson
Medtronic
Express Scripts
Colorcon

Last Updated: August 11, 2022

Investigational Drug Information for SHR3824


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug SHR3824?

SHR3824 is an investigational drug.

There have been 15 clinical trials for SHR3824. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2017.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Liver Diseases. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Shandong Suncadia Medicine Co., Ltd., and [disabled in preview].

There are three US patents protecting this investigational drug and thirty-five international patents.

Recent Clinical Trials for SHR3824
TitleSponsorPhase
A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese SubjectsShandong Suncadia Medicine Co., Ltd.Phase 1
A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy VolunteersShandong Suncadia Medicine Co., Ltd.Phase 1
Drug-drug Interaction Between Simvastatin and SHR3824Jiangsu HengRui Medicine Co., Ltd.Phase 1

See all SHR3824 clinical trials

Clinical Trial Summary for SHR3824

Top disease conditions for SHR3824
Top clinical trial sponsors for SHR3824

See all SHR3824 clinical trials

US Patents for SHR3824

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SHR3824 See Plans and Pricing L-proline complex of sodium-glucose cotransporter 2 inhibitor, monohydrate and crystal form thereof Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) See Plans and Pricing
SHR3824 See Plans and Pricing Compounds as peptidic GLP1/glucagon/GIP receptor agonists SANOFI (Paris, FR) See Plans and Pricing
SHR3824 See Plans and Pricing Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists SANOFI (Paris, FR) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SHR3824

Drugname Country Document Number Estimated Expiration Related US Patent
SHR3824 Brazil BR112017005454 2034-09-30 See Plans and Pricing
SHR3824 Canada CA2961819 2034-09-30 See Plans and Pricing
SHR3824 China CN105992769 2034-09-30 See Plans and Pricing
SHR3824 European Patent Office EP3202772 2034-09-30 See Plans and Pricing
SHR3824 Spain ES2836099 2034-09-30 See Plans and Pricing
SHR3824 Hungary HUE052588 2034-09-30 See Plans and Pricing
SHR3824 Japan JP2017530107 2034-09-30 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Johnson and Johnson
Medtronic
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.